27320055|t|Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells
27320055|a|Designer drugs such as synthetic psychostimulants are indicative of a worldwide problem of drug abuse and addiction. In addition to methamphetamine (METH), these drugs include 3,4-methylenedioxy-methamphetamine (MDMA) and commercial preparations of synthetic cathinones including 3,4-methylenedioxypyrovalerone (MDPV), typically referred to as " bath salts ." These psychostimulants exert neurotoxic effects by altering monoamine systems in the brain. Additionally, METH and MDMA adversely affect the integrity of the blood-brain barrier (BBB): there are no current reports on the effects of MDPV on the BBB. The aim of this study was to compare the effects of METH, MDMA and MDPV on bovine brain microvessel endothelial cells (bBMVECs), an accepted in vitro model of the BBB. Confluent bBMVEC monolayers were treated with METH, MDMA and MDPV (0.5mM-2.5mM) for 24h. METH and MDMA increased lactate dehydrogenase release only at the highest concentration (2.5mM), whereas MDPV induced cytotoxicity at all concentration s. MDMA and METH decreased cellular proliferation only at 2.5mM, with similar effects observed after MDPV exposures starting at 1mM. Only MDPV increased reactive oxygen species production at all concentrations tested whereas all 3 drugs increased nitric oxide production. Morphological analysis revealed different patterns of compound - induced cell damage. METH induced vacuole formatio n at 1mM and disruption of the monolayer at 2.5mM. MDMA induced disruption of the endothelial monolayer from 1mM without vacuolization. On the other hand, MDPV induced monolayer disruption at doses â‰¥0.5mM without vacuole formation; at 2.5mM, the few remaining cells lacked endothelial morphology. These data suggest that even though these synthetic psychostimulants alter monoaminergic systems, they each induce BBB toxicity by different mechanisms with MDPV being the most toxic.
27320055	0	15	Methamphetamine	T109,T131	C0025611
27320055	17	50	3,4-methylenedioxymethamphetamine	T109,T121,T131	C0115471
27320055	52	56	MDMA	T109,T121,T131	C0115471
27320055	62	92	3,4-methylenedioxypyrovalerone	T109	C2974592
27320055	94	98	MDPV	T109	C2974592
27320055	100	106	induce	T169	C0205263
27320055	107	119	differential	T080	C0443199
27320055	120	137	cytotoxic effects	T049	C0596402
27320055	141	147	bovine	T015	C0007452
27320055	148	153	brain	T023	C0006104
27320055	154	165	microvessel	T023	C2350570
27320055	166	183	endothelial cells	T025	C0225336
27320055	184	198	Designer drugs	T131	C0011684
27320055	207	233	synthetic psychostimulants	T121	C0304403
27320055	264	271	problem	T033	C0033213
27320055	275	285	drug abuse	T048	C0013146
27320055	290	299	addiction	T048	C1510472
27320055	316	331	methamphetamine	T109,T131	C0025611
27320055	333	337	METH	T109,T131	C0025611
27320055	346	351	drugs	T131	C0011684
27320055	360	394	3,4-methylenedioxy-methamphetamine	T109,T121,T131	C0115471
27320055	396	400	MDMA	T109,T121,T131	C0115471
27320055	406	416	commercial	T170	C0680536
27320055	417	429	preparations	T052	C1521827
27320055	433	453	synthetic cathinones	T109,T121	C0054876
27320055	464	494	3,4-methylenedioxypyrovalerone	T109	C2974592
27320055	496	500	MDPV	T109	C2974592
27320055	530	540	bath salts	T109,T121	C0771243
27320055	550	566	psychostimulants	T121	C0304403
27320055	573	591	neurotoxic effects	T037	C0235032
27320055	595	603	altering	T078	C1515926
27320055	604	621	monoamine systems	UnknownType	C0815020
27320055	629	634	brain	T023	C0006104
27320055	650	654	METH	T109,T131	C0025611
27320055	659	663	MDMA	T109,T121,T131	C0115471
27320055	664	680	adversely affect	T046	C0879626
27320055	685	694	integrity	T080	C1947912
27320055	702	721	blood-brain barrier	T023	C0005854
27320055	723	726	BBB	T023	C0005854
27320055	750	757	reports	T170	C0684224
27320055	765	775	effects of	T080	C1704420
27320055	776	780	MDPV	T109	C2974592
27320055	788	791	BBB	T023	C0005854
27320055	809	814	study	T062	C2603343
27320055	822	829	compare	T052	C1707455
27320055	834	844	effects of	T080	C1704420
27320055	845	849	METH	T109,T131	C0025611
27320055	851	855	MDMA	T109,T121,T131	C0115471
27320055	860	864	MDPV	T109	C2974592
27320055	868	874	bovine	T015	C0007452
27320055	875	880	brain	T023	C0006104
27320055	881	892	microvessel	T023	C2350570
27320055	893	910	endothelial cells	T025	C0225336
27320055	912	919	bBMVECs	T025	C0225336
27320055	934	948	in vitro model	T062	C1515654
27320055	956	959	BBB	T023	C0005854
27320055	961	970	Confluent	T080	C0205200
27320055	971	977	bBMVEC	T025	C0225336
27320055	978	988	monolayers	T023	C0934502
27320055	994	1001	treated	T169	C1522326
27320055	1007	1011	METH	T109,T131	C0025611
27320055	1013	1017	MDMA	T109,T121,T131	C0115471
27320055	1022	1026	MDPV	T109	C2974592
27320055	1050	1054	METH	T109,T131	C0025611
27320055	1059	1063	MDMA	T109,T121,T131	C0115471
27320055	1064	1073	increased	T081	C0205217
27320055	1074	1095	lactate dehydrogenase	T116,T126	C0022917
27320055	1096	1103	release	T169	C1283071
27320055	1116	1123	highest	T080	C1522410
27320055	1124	1137	concentration	T081	C1446561
27320055	1155	1159	MDPV	T109	C2974592
27320055	1160	1167	induced	T169	C0205263
27320055	1168	1180	cytotoxicity	T049	C0596402
27320055	1188	1201	concentration	T081	C1446561
27320055	1205	1209	MDMA	T109,T121,T131	C0115471
27320055	1214	1218	METH	T109,T131	C0025611
27320055	1219	1228	decreased	T081	C0205216
27320055	1229	1251	cellular proliferation	T043	C0596290
27320055	1280	1287	effects	T080	C1280500
27320055	1303	1307	MDPV	T109	C2974592
27320055	1308	1317	exposures	T080	C0332157
27320055	1340	1344	MDPV	T109	C2974592
27320055	1345	1354	increased	T081	C0205217
27320055	1355	1378	reactive oxygen species	T123,T196	C0162772
27320055	1379	1389	production	T052	C1883254
27320055	1397	1411	concentrations	T081	C1446561
27320055	1412	1418	tested	T169	C0039593
27320055	1433	1438	drugs	T131	C0011684
27320055	1439	1448	increased	T081	C0205217
27320055	1449	1461	nitric oxide	T121,T123,T197	C0028128
27320055	1462	1472	production	T052	C1883254
27320055	1474	1496	Morphological analysis	T062	C0936012
27320055	1506	1515	different	T080	C1705242
27320055	1528	1536	compound	T103	C1706082
27320055	1539	1546	induced	T169	C0205263
27320055	1547	1558	cell damage	T049	C0599732
27320055	1560	1564	METH	T109,T131	C0025611
27320055	1565	1572	induced	T169	C0205263
27320055	1573	1580	vacuole	T026	C0042219
27320055	1581	1589	formatio	T169	C1522492
27320055	1603	1613	disruption	T169	C0332453
27320055	1621	1630	monolayer	T023	C0934502
27320055	1641	1645	MDMA	T109,T121,T131	C0115471
27320055	1646	1653	induced	T169	C0205263
27320055	1654	1664	disruption	T169	C0332453
27320055	1672	1683	endothelial	T025	C0225336
27320055	1684	1693	monolayer	T023	C0934502
27320055	1711	1724	vacuolization	T033	C0010840
27320055	1745	1749	MDPV	T109	C2974592
27320055	1750	1757	induced	T169	C0205263
27320055	1758	1767	monolayer	T023	C0934502
27320055	1768	1778	disruption	T169	C0332453
27320055	1782	1787	doses	T081	C0178602
27320055	1803	1810	vacuole	T026	C0042219
27320055	1811	1820	formation	T169	C1522492
27320055	1850	1855	cells	T025	C0007634
27320055	1863	1885	endothelial morphology	T080	C0332437
27320055	1893	1897	data	T078	C1511726
27320055	1929	1955	synthetic psychostimulants	T121	C0304403
27320055	1962	1983	monoaminergic systems	UnknownType	C0815020
27320055	1995	2001	induce	T169	C0205263
27320055	2002	2005	BBB	T023	C0005854
27320055	2006	2014	toxicity	T037	C0013221
27320055	2018	2027	different	T080	C1705242
27320055	2028	2038	mechanisms	T169	C0441712
27320055	2044	2048	MDPV	T109	C2974592
27320055	2064	2069	toxic	T080	C1407029